Featured
Preclinical Study Shows Selective A2B Receptor Inhibitor Enhances Mesothelioma Immunotherapy Preclinical Study Shows Selective A2B Receptor Inhibitor Enhances Mesothelioma Immunotherapy Reviewed by Unknown on October 23, 2025 Rating: 5
Connecticut Judge Increases Johnson & Johnson Mesothelioma Verdict to $25 Million  Connecticut Judge Increases Johnson & Johnson Mesothelioma Verdict to $25 MillionĀ  Reviewed by Unknown on October 06, 2025 Rating: 5
Australia Reports Steady Mesothelioma Incidence, Improving Survival Australia Reports Steady Mesothelioma Incidence, Improving Survival Reviewed by Unknown on September 12, 2025 Rating: 5
Clinical Trial Shows Promise for Mesothelioma Immunotherapy Protocol Clinical Trial Shows Promise for Mesothelioma Immunotherapy Protocol Reviewed by Unknown on September 10, 2025 Rating: 5
Researchers Report Promising Results from NERO Mesothelioma Study Researchers Report Promising Results from NERO Mesothelioma Study Reviewed by Unknown on May 01, 2025 Rating: 5
Montana Mesothelioma Claimants Targeted by State House Proposed Bill Montana Mesothelioma Claimants Targeted by State House Proposed Bill Reviewed by Unknown on March 17, 2025 Rating: 5
Mesothelioma Victim’s Survivors Win Right to Have Case Heard Locally Mesothelioma Victimā€™s Survivors Win Right to Have Case Heard Locally Reviewed by Unknown on December 16, 2024 Rating: 5
Subscribe to: Comments ( Atom )
Powered by Blogger.